Promising Results With Aleglitazar, A New Treatment Drug For Type 2 Diabetes (SYNCHRONY Study)

The results from the phase II SYNCHRONY study are published in an article Online First and in a future edition of The Lancet. At the same time, the findings are presented at the American Diabetes Association meeting in New Orleans, USA. They suggest that aleglitazar, a treatment for type 2 diabetes, might be safe and effective and may perhaps be introduced into phase III trials. Aleglitazar belongs to a class of drug called PPAR co-agonists.

More: continued here

Filed under: Diabetes on June 10th, 2009